noCryptolepine is the major alkaloid of the West African shrub, Cryptolepis sanguinolenta. Cryptolepine has\ud been shown to inhibit nitric oxide production, and DNA binding of Nuclear Factor-kappa B following\ud inflammatory stimuli in vitro. In order to validate the anti-inflammatory property of this compound in vivo,\ud we investigated its effects on a number of animal models of inflammation. Cryptolepine (10¿40 mg/kg i.p.)\ud produced significant dose-dependent inhibition of the carrageenan-induced rat paw oedema, and carrageenaninduced\ud pleurisy in rats. These effects were compared with those of the non-steroidal anti-inflammatory drug\ud indomethacin (10 mg/kg). At doses of 10¿40 mg/kg i.p., cryptolepine inhibited lipopolysaccharide (LPS)-induced\ud microvascular permeability in mice in a dose-related fashion. Oral administration of up to 40 mg/kg of the\ud compound for four consecutive days did not induce gastric lesion formation in rats. Analgesic activity was also\ud exhibited by cryptolepine through a dose-related (10¿40 mg/kg i.p.) inhibition of writhing induced by i.p.\ud administration of acetic acid in mice. The results of this study reveal that cryptolepine possesses in vivo\ud anti-inflammatory activity.Copyright © 2009 John Wiley & Sons, Ltd
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.